<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005666</url>
  </required_header>
  <id_info>
    <org_study_id>CRL/CT/09/11-12</org_study_id>
    <nct_id>NCT02005666</nct_id>
  </id_info>
  <brief_title>To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel</brief_title>
  <official_title>A Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study to Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel (of Cadila Healthcare Limited, India) Versus DUAC® Gel (of Stiefel Laboratories, USA) Versus Placebo (Vehicle Gel) in the Ratio of 2:2:1 Respectively, in Patients With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadila Healthcare Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cadila Healthcare Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo
      Controlled, Three Arm Clinical Study.

      The main objective is to evaluate bioequivalence of Test formulation (Clindamycin Phosphate
      1.2%/Benzoyl peroxide 5% gel) of Cadila Healthcare with Reference formulation (DUAC® Gel of
      Stiefel Laboratories)in the ratio of 2:2:1 of Test drug, Reference drug and Placebo
      respectively.

      Total study duration will be for a period of 78 days which includes treatment duration of 77
      days.

      850 subjects will be enrolled (randomized)as per the inclusion and exclusion criteria
      mentioned in the protocol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">September 28, 2016</completion_date>
  <primary_completion_date type="Actual">September 28, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent change from baseline to week 11 (study Day 77) for inflammatory (papules and pustules) lesions.</measure>
    <time_frame>week 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline to week 11 in the non-inflammatory lesion count</measure>
    <time_frame>week 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a clinical response of &quot;success&quot; at week 11</measure>
    <time_frame>Week 11</time_frame>
    <description>Success will be defined as an IGA score that is at least 2 grades less than the baseline assessment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">850</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Test-Cadila healthcare limited</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:-Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug:-DUAC® Gel (of Stiefel Laboratories, USA) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug:-Placebo (Vehicle Gel) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel</intervention_name>
    <description>Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
    <arm_group_label>Test-Cadila healthcare limited</arm_group_label>
    <other_name>1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of CHL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DUAC® Gel</intervention_name>
    <description>Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
    <arm_group_label>Reference</arm_group_label>
    <other_name>DUAC® Gel (of Stiefel Laboratories</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug:-Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo (Vehicle Gel)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or non pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis
             of Acne vulgaris

          2. On the face, ≥ 25 non-inflammatory lesions (i.e., open and closed comedones) AND ≥ 20
             inflammatory lesions (i.e., papules and pustules) AND ≤ 2 nodulocystic lesions (i.e.,
             nodules and cysts).

          3. Investigator's Global Assessment (IGA) of acne severity grade 2, 3 OR 4

          4. Willing to refrain from use of all other topical acne medications or antibiotics
             during the 11 week treatment period.

          5. If female of childbearing potential, willing to use an acceptable form of birth
             control during the study.

          6. Have used the same brand of make-up for a minimum period of 2 weeks prior to
             randomization, for subjects who use make-up, and agree to not change make-up brands or
             types during the study.

          7. Willing to provide written informed consent or assent (HIPAA consent/authorization, as
             applicable)

        Exclusion Criteria:

          1. Presence of any skin condition that would interfere with the diagnosis or assessment
             of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell
             carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid
             folliculitis, or bacterial folliculitis).

          2. Patients who have acne conglobata, acne fulminans and secondary acne (e.g.: chloracne
             and drug induced acne).

          3. Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere
             with diagnosis or assessment of acne vulgaris. Well trimmed moustaches are allowed.

          4. History of hypersensitivity or allergy to benzoyl peroxide or clindamycin and/or any
             of the study medication ingredients.

          5. Patients who have a severe or intense irritation on the Face.

          6. Use within 6 months prior to baseline (Randomization) of oral retinoids (e.g.
             Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day
             (multivitamins are allowed).

          7. Use for less than 3 months prior to baseline (Randomization) of estrogens or oral
             contraceptives; use of such therapy is allowed if it will remain constant throughout
             the study.

          8. Use on the face within 1 month prior to baseline (Randomization) or during the study
             of: 1) cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy,
             4) acne surgery, 5) intralesional steroids, or 6) x-ray therapy.

          9. Use within 1 month prior to baseline (Randomization) of: 1) spironolactone, 2)
             systemic steroids, 3) systemic antibiotics, 4) systemic treatment for acne vulgaris
             (other than oral retinoids, which require a 6-month washout), or 5) systemic
             anti-inflammatory agents.

         10. Use within 2 weeks prior to baseline (Randomization) of: 1) topical steroids, 2)
             topical retinoids, 3) topical acne treatments including over-the-counter preparations,
             4) topical anti-inflammatory agents, 5) medicated cleansers or 6) topical antibiotics.

         11. Patients who have had general anesthesia for any reason and patients who have received
             neuromuscular blocking agents within 14 days prior to study entry (Randomization).

         12. Concomitant use of facial product containing glycolic or other acids, masks, washes or
             soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or
             moisturizers containing retinol, salicylic or α- or β-hydroxy acids.

         13. Concomitant use of mega-doses of certain vitamins (such as vitamin D and vitamin B12),
             haloperidol, halogens such as iodide and bromide, lithium, hydantoin and
             phenobarbital.

         14. Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 2
             weeks or during the study.

         15. Concomitant use of tanning booths or sunbathing.

         16. A significant medical history of or are currently immunocompromised

         17. Have any systemic or dermatologic disease that may affect the evaluation of study
             results.

         18. Have a history of regional enteritis, ulcerative colitis, pseudomembranous colitis or
             antibiotic-associated colitis.

         19. Subjects with clinically significant unstable medical disorders, life-threatening
             disease, or current malignancies.

         20. Subjects who engage in activities that involve excessive or prolonged exposure to
             sunlight.

         21. Subjects with History of Alcohol abuse or other drugs of abuse within 2 years prior to
             Randomization.

         22. Female subjects who are breast-feeding or planning to become pregnant.

         23. Subjects who have been treated with an investigational drug or investigational device
             within a period of 30 days prior to study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Charu Gautam, M.D,DNB</last_name>
    <role>Study Director</role>
    <affiliation>Cliantha Research Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universal BioPharma Research</name>
      <address>
        <city>Dinuba</city>
        <state>California</state>
        <zip>93618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Instititue</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yardley Dermatology Associates</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <zip>19067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discover Research</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osmania General Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gandhi Hospital,</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500048</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George Hospital</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andrapradesh</state>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maulana Azad Medical College</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHL Medical College and VS Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC-MET Medical College, Sheth LG General Hospital,</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanjeevani Hospital,</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, Leprosy and STI, Civil Hospital and BJ Medical College,</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, BYL Nair Hospital and TN medical college, Dr ALNair Road, Mumbai Central,</name>
      <address>
        <city>Mumbai</city>
        <state>Gujarat</state>
        <zip>400 008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, New Civil Hospital and Government Medical College</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baroda Medical College</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, Bhagawan Mahaveer Jain Hospital Millers Road,Vasanthnagar -</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, Kempegowda Institute of Medical Sciences</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapthagiri Hospital,</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560073</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Skin &amp; STD, JSS Hospital Ramanuja Road, -</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <zip>570004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Government Medical Collge</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NKP Salve Institute of Medical Siences and Lata Mangeshkar Hospital,</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. D Y Patil Hospital and Research Center</name>
      <address>
        <city>Navi Mumbai</city>
        <state>Maharashtra</state>
        <zip>400706</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jehangir Clinical Development Center</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medipoint Hosp</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411007.</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Postgraduate Institute of Medical Education &amp; Research (PGIMER)</name>
      <address>
        <city>Chandigarh</city>
        <state>Punjab</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.V. Hospital and research Center</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Post graduate medical and Research</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ganga Ram Hospital,</name>
      <address>
        <city>Delhi</city>
        <zip>110 060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aafp.org/afp/2004/0501/p2123.html</url>
    <description>1. Feldman S, Careccia RE, Barham KL, et al. Diagnosis and treatment of acne. Am Fam Physician</description>
  </link>
  <link>
    <url>http://www.bioline.org.br/pdf?dv09082</url>
    <description>2. NilFroushzadeh MA, Siadat AH, Baradaran EH, Moradi S. Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus Tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to</description>
  </link>
  <link>
    <url>http://www.jahonline.org/article/S1054-139X(08)00271-1/abstract</url>
    <description>3. Irby CE, Yentzer BA, Feldman SR. A Review of Adapalene in the Treatment of Acne Vulgaris. Journal of Adolescent Health</description>
  </link>
  <link>
    <url>http://www.eblue.org/article/S0190-9622(82)70109-4/abstract</url>
    <description>6. Barza M, Goldstein JA, Kane A. Systemic absorption of clindamycin hydrochloride after topical application. Journal of the American Academy of Dermatology</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16509</url>
    <description>Cleocin T® Prescribing Information</description>
  </link>
  <link>
    <url>http://www.eblue.org/article/S0190-9622(82)70116-1/abstract</url>
    <description>Guin JD, Lummis WL. Comedonal levels of free clindamycin following topical treatment with a 1% solution of clindamycin phosphate. Journal of the American Academy of Dermatology</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC172501</url>
    <description>Plaisnce KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC. Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother</description>
  </link>
  <link>
    <url>http://www.springerlink.com/content/p64073257n8t7216</url>
    <description>Brodasky TF, Lewis C, Eble TE. Distribution and metabolism of Antibiotics in the whole animal I. clindamycin in the rat</description>
  </link>
  <link>
    <url>http://www.eblue.org/article/S0190-9622(81)70004-5/abstract</url>
    <description>Nacht S, Yeung D, Beasley JN, Anjo MD, Maibach HI. Benzoyl peroxide: percutaneous penetration and metabolic disposition. Journal of the American Academy of Dermatology</description>
  </link>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050741s019lbl.pdf</url>
    <description>DUAC® Gel Prescribing Information</description>
  </link>
  <link>
    <url>http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071292.pdf</url>
    <description>U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Draft Guidance for Industry: Acne Vulgaris: Developing Drugs for Treatment.</description>
  </link>
  <reference>
    <citation>Eller MG, Smith RB, Phillips JP. Absorption kinetics of topical clindamycin preparations. Biopharm Drug Dispos. 1989 Sep-Oct;10(5):505-12.</citation>
    <PMID>2804254</PMID>
  </reference>
  <reference>
    <citation>Zouboulis CC, Fischer TC, Wohlrab J, Barnard J, Alió AB. Study of the efficacy, tolerability, and safety of 2 fixed-dose combination gels in the management of acne vulgaris. Cutis. 2009 Oct;84(4):223-9.</citation>
    <PMID>19911678</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <keyword>DUAC</keyword>
  <keyword>CADILA</keyword>
  <keyword>CLIANTHA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

